Seminars in Oncology
Volume 34, Issue 5 , Pages 411-417, October 2007

Strategies for Identifying Hereditary Nonpolyposis Colon Cancer

  • D. Gareth Evans

      Affiliations

    • Academic Unit of Medical Genetics, Regional Genetics Service, St Mary’s Hospital, Manchester, UK.
    • Corresponding Author InformationAddress correspondence to D. Gareth Evans, MD, FRCP, Professor in Medical Genetics, Department of Clinical Genetics, St. Mary’s Hospital (SM2), Hathersage Road, Manchester M13 OJH, UK.
  • ,
  • Sheila Walsh

      Affiliations

    • Department of Surgery, Trafford General Hospital, Manchester, UK.
  • ,
  • James Hill

      Affiliations

    • Department of Surgery, Manchester Royal Infirmary, Manchester, UK.
  • ,
  • Raymond T. McMahon

      Affiliations

    • Department of Histopathology, Manchester Royal Infirmary, Manchester, UK.
    • Division of Regenerative Medicine, University of Manchester, Manchester, UK.

Hereditary nonpolyposis colorectal cancer (HNPCC) is the term given to a predisposition syndrome caused by inherited mutations in one of at least five DNA mismatch repair (MMR) genes. Dominant mutations in these genes predispose individuals to a range of cancers in addition to the most frequent, colorectal cancer. Endometrial cancer is the most notable additional malignancy, followed by ovarian, gastric, upper urethelial, and biliary cancers, and gliomas. Recognition of HNPCC is important so that targeted screening can be effected that will reduce the incidence of the main cancers. While such clinical criteria as Amsterdam and modified Amsterdam are reasonably specific, they lack sensitivity. Thus, tumor-related features have been used to improve sensitivity for identifying patients who can be selected for the relatively expensive direct mutation analysis of the various genes. Microsatellite instability (MSI) and loss of antibody staining for the proteins have been widely vaunted but have their own drawbacks. No one approach has received universal acceptance, and therefore adoption of one of perhaps three strategies, including clinical- and laboratory-based approaches, is still appropriate until an easier, quicker, and cheaper approach can be developed.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(07)00138-8

doi:10.1053/j.seminoncol.2007.07.001

Seminars in Oncology
Volume 34, Issue 5 , Pages 411-417, October 2007